Ipsen SA (EURONEXT:IPN) said its Phase III BOLD trial of odevixibat in biliary atresia missed the primary endpoint for native liver survival, though safety matched approved use and an open‑label extension continues, as the company also corrected July 22 voting‑rights figures for June 30.
Previous Week Recap
- BOLD Trial Missed Endpoint: Ipsen (IPN): Phase III BOLD trial of odevixibat in biliary atresia missed primary endpoint for native liver survival; safety profile consistent with approved use and open‑label extension ongoing.
- Ipsen Corrects Share Figures: Ipsen SA corrected its June 30, 2026 shares and voting rights figures on July 22, 2026, revising gross and net voting rights totals and clarifying threshold definitions for disclosures.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.